Revex, Selincro(nalmefene)
Nalmefene, Opvee, Selincro, Zurnai (nalmefene) is a small molecule pharmaceutical. Nalmefene was first approved as Revex on 1995-04-17. It is used to treat drug overdose, opioid-related disorders, and respiration disorders in the USA. It has been approved in Europe to treat alcohol-related disorders. The pharmaceutical is active against mu-type opioid receptor and kappa-type opioid receptor. In addition, it is known to target delta-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nalmefene, Opvee, Zurnai (discontinued: Revex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nalmefene hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OPVEE | Indivior | N-217470 RX | 2023-05-22 | 1 products, RLD, RS |
| ZURNAI (AUTOINJECTOR) | Purdue Pharma | N-218590 RX | 2024-08-07 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nalmefene hydrochloride | ANDA | 2023-12-08 |
| opvee | New Drug Application | 2023-11-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| opioid-related disorders | EFO_0005611 | D009293 | F11 |
| respiration disorders | — | D012120 | J00-J99 |
| drug overdose | — | D062787 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
NALMEFENE HYDROCHLORIDE, OPVEE, INDIVIOR | |||
| 2026-05-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Nalmefene Hydrochloride, Opvee, Indivior | |||
| 11458091 | 2038-07-10 | DP | U-3630 |
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 4 | 2 | 6 | 4 | 3 | 18 |
| Opiate overdose | D000083682 | — | — | 1 | — | 1 | 1 | — | 3 |
| Resuscitation | D012151 | — | — | — | — | — | 1 | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | 2 | 1 | — | 1 | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | 1 | 1 | — | — | 1 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | — | 1 | — | — | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | — | 1 |
| Drug overdose | D062787 | — | — | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | — | — | 1 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | — | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | — | — | — | 1 |
| Impulsive behavior | D007175 | — | — | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Impulse control disruptive and conduct disorders | D007174 | — | F63.2 | — | 1 | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Alcoholic intoxication | D000435 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
| Hyperalgesia | D006930 | — | — | — | — | — | — | 1 | 1 |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nalmefene |
| INN | nalmefene |
| Description | Nalmefene is a morphinane alkaloid. |
| Classification | Small molecule |
| Drug class | narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5 |
Identifiers
| PDB | — |
| CAS-ID | 55096-26-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL982 |
| ChEBI ID | 7457 |
| PubChem CID | 5284594 |
| DrugBank | DB06230 |
| UNII ID | TOV02TDP9I (ChemIDplus, GSRS) |
Target
Agency Approved
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,133 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
252 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use